Catalyst Pharmaceuticals Future Growth
Future criteria checks 4/6
Catalyst Pharmaceuticals is forecast to grow earnings and revenue by 20% and 12% per annum respectively. EPS is expected to grow by 18.7% per annum. Return on equity is forecast to be 18.9% in 3 years.
Key information
20.0%
Earnings growth rate
18.7%
EPS growth rate
Biotechs earnings growth | 24.6% |
Revenue growth rate | 12.0% |
Future return on equity | 18.9% |
Analyst coverage | Good |
Last updated | 06 Jun 2024 |
Recent future growth updates
Recent updates
Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)
Apr 06Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)
Jan 29Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk
Jan 17With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case
Sep 06Should You Be Adding Catalyst Pharmaceuticals (NASDAQ:CPRX) To Your Watchlist Today?
May 27Do Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings Warrant Your Attention?
Feb 13Is Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist?
Nov 11Catalyst Pharmaceuticals gains 9% on SmallCap 600 addition
Sep 12Catalyst Pharma ends momentum as Roth downgrades
Aug 24Catalyst Pharmaceuticals: Performing Above Expectations
Aug 12Catalyst: Upside Outlier - In Search Of A Catalyst
May 11Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 611 | 185 | 239 | N/A | 4 |
12/31/2025 | 543 | 161 | 211 | 243 | 7 |
12/31/2024 | 462 | 117 | 158 | 186 | 7 |
3/31/2024 | 411 | 65 | 46 | 163 | N/A |
12/31/2023 | 398 | 71 | -136 | 144 | N/A |
9/30/2023 | 348 | 62 | -114 | 128 | N/A |
6/30/2023 | 303 | 116 | -48 | 124 | N/A |
3/31/2023 | 256 | 99 | -53 | 120 | N/A |
12/31/2022 | 214 | 83 | 106 | 116 | N/A |
9/30/2022 | 192 | 67 | 85 | 95 | N/A |
6/30/2022 | 170 | 54 | 75 | 76 | N/A |
3/31/2022 | 154 | 45 | 65 | 65 | N/A |
12/31/2021 | 141 | 39 | 59 | 60 | N/A |
9/30/2021 | 134 | 42 | 53 | 54 | N/A |
6/30/2021 | 127 | 75 | 43 | 44 | N/A |
3/31/2021 | 120 | 72 | 41 | 42 | N/A |
12/31/2020 | 119 | 75 | 45 | 45 | N/A |
9/30/2020 | 118 | 71 | 44 | 44 | N/A |
6/30/2020 | 120 | 42 | 49 | 49 | N/A |
3/31/2020 | 119 | 43 | 50 | 50 | N/A |
12/31/2019 | 102 | 32 | 35 | 35 | N/A |
9/30/2019 | 73 | 9 | 14 | 14 | N/A |
6/30/2019 | 42 | -12 | -9 | -9 | N/A |
3/31/2019 | 13 | -29 | -28 | -28 | N/A |
12/31/2018 | 1 | -34 | -26 | -26 | N/A |
9/30/2018 | N/A | -25 | -22 | -22 | N/A |
6/30/2018 | N/A | -21 | -18 | -18 | N/A |
3/31/2018 | N/A | -19 | -16 | -16 | N/A |
12/31/2017 | N/A | -18 | N/A | -14 | N/A |
9/30/2017 | N/A | -17 | N/A | -14 | N/A |
6/30/2017 | N/A | -17 | N/A | -15 | N/A |
3/31/2017 | N/A | -18 | N/A | -16 | N/A |
12/31/2016 | N/A | -18 | N/A | -18 | N/A |
9/30/2016 | N/A | -20 | N/A | -18 | N/A |
6/30/2016 | N/A | -20 | N/A | -20 | N/A |
3/31/2016 | N/A | -20 | N/A | -20 | N/A |
12/31/2015 | N/A | -20 | N/A | -18 | N/A |
9/30/2015 | N/A | -18 | N/A | -17 | N/A |
6/30/2015 | N/A | -18 | N/A | -16 | N/A |
3/31/2015 | N/A | -17 | N/A | -14 | N/A |
12/31/2014 | N/A | -16 | N/A | -13 | N/A |
9/30/2014 | N/A | -13 | N/A | -13 | N/A |
6/30/2014 | N/A | -14 | N/A | -11 | N/A |
3/31/2014 | N/A | -14 | N/A | -10 | N/A |
12/31/2013 | N/A | -12 | N/A | -10 | N/A |
9/30/2013 | N/A | -11 | N/A | -7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CPRX's forecast earnings growth (20% per year) is above the savings rate (2.4%).
Earnings vs Market: CPRX's earnings (20% per year) are forecast to grow faster than the US market (14.8% per year).
High Growth Earnings: CPRX's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: CPRX's revenue (12% per year) is forecast to grow faster than the US market (8.6% per year).
High Growth Revenue: CPRX's revenue (12% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CPRX's Return on Equity is forecast to be low in 3 years time (18.9%).